Kim Sang Jin, Yu Hyeong Gon
Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.
Ocul Immunol Inflamm. 2007 Sep-Oct;15(5):381-7. doi: 10.1080/09273940701624312.
To evaluate treatment outcomes with low-dose azathioprine in Vogt-Koyanagi-Harada (VKH) disease patients.
Retrospective case series.
Medical records of consecutive patients with VKH disease were reviewed. Azathioprine was administered in cases with corticosteroid intolerance or uncontrolled inflammation. Corticosteroid sparing effect, visual acuity, corticosteroid dose, and complication rates were evaluated.
Sixteen of 34 VKH patients included in this study underwent azathioprine therapy with systemic corticosteroid. Six patients received azathioprine in the acute uveitic phase and 10 patients in the chronic recurrent phase. A corticosteroid sparing effect was achieved in 86.5% of patients given azathioprine in the acute uveitic phase and 90.0% of patients given in the chronic recurrent phase. Median time to corticosteroid sparing effect was 3.5 months. Twelve of 16 patients showed improved activity in 1 month after initiation of azathioprine therapy.
Low-dose azathioprine therapy may be effective as corticosteroid sparing agent in VKH disease.
评估低剂量硫唑嘌呤对葡萄膜炎-小柳原田（VKH）病患者的治疗效果。
回顾性病例系列研究。
回顾连续性VKH病患者的病历。在对皮质类固醇不耐受或炎症无法控制的病例中使用硫唑嘌呤。评估皮质类固醇的减量效果、视力、皮质类固醇剂量及并发症发生率。
本研究纳入的34例VKH病患者中，16例接受了硫唑嘌呤联合全身皮质类固醇治疗。6例患者在葡萄膜炎急性期接受硫唑嘌呤治疗，10例患者在慢性复发期接受治疗。在急性期接受硫唑嘌呤治疗的患者中，86.5%实现了皮质类固醇减量效果，在慢性复发期接受治疗的患者中，这一比例为90.0%。实现皮质类固醇减量效果的中位时间为3.5个月。16例患者中有12例在开始硫唑嘌呤治疗1个月后病情活动改善。
低剂量硫唑嘌呤治疗可能作为VKH病的皮质类固醇减量药物有效。
